This marks a significant step forward in the multi-regional
partnership between Deciphera and Medison
ZUG, Switzerland and
TORONTO, Sept. 29, 2023 /PRNewswire/ -- Today, Medison
Pharma ("Medison"), a global pharma company focused on providing
access to highly innovative therapies to patients in international
markets, is pleased to announce the public formulary listing of
QINLOCK® in Canadian provinces: Ontario and Quebec. These provinces join Alberta, Saskatchewan, Manitoba, and the Non-Insured Health Benefits
(NIHB) program, further broadening the public formulary coverage
for adult patients with advanced gastrointestinal stromal tumor
(GIST) who have previously been treated with imatinib, sunitinib,
and regorafenib.
QINLOCK was developed by Deciphera Pharmaceuticals (NASDAQ:
DCPH), a biopharmaceutical company focused on discovering,
developing, and commercializing important new medicines to improve
the lives of people with cancer.
With the recent expansion of QINLOCK's listing, Medison, having
entered into a multi-regional partnership with Deciphera in
November 2020, remains committed to
accelerating access for fourth-line GIST patients in an increasing
number of provinces across Canada.
"Our profound commitment to the patients and communities we
serve drives our ongoing efforts to broaden access to QINLOCK. Now
covered in five pivotal provinces and the NIHB, we are dedicated to
ensuring that every advanced GIST patient in the remaining
provinces in Canada will have
access to this treatment," remarks Pamela
Minden, Country Manager at Medison Pharma in Canada.
"Advanced GIST is a very rare and complex disease," said Dr.
Albiruni Razak, Medical Oncologist, Princess Margaret Cancer
Centre and Mount Sinai Hospital. "Following its availability
in late 2020, QINLOCK has offered patients with 4L GIST new
hope. The addition of provincial formulary coverage for this
important product is a welcome advancement."
GIST is a cancer that occurs in the gastrointestinal tract, most
commonly in the stomach or small intestine. Soft tissue cancers
such as GIST are very rare and comprise about one per cent of all
cancers.[i]
About QINLOCK (ripretinib)[ii]
QINLOCK is a switch-control tyrosine kinase inhibitor that was
engineered to broadly inhibit KIT and PDGFRA mutated kinases by
using a dual mechanism of action that regulates the kinase switch
pocket and activation loop. QINLOCK inhibits primary and secondary
KIT mutations in exons 9, 11, 13, 14, 17, and 18 involved in GIST,
as well as the primary exon 17 D816V mutation. QINLOCK also
inhibits primary PDGFRA mutations in exons 12, 14, and 18,
including the exon 18 D842V mutation, involved in a subset of
GIST.
QINLOCK is approved by Health Canada and indicated for the
treatment of adult patients with advanced gastrointestinal stromal
tumor (GIST) who have received prior treatment with imatinib,
sunitinib, and regorafenib.
QINLOCK was developed by Deciphera Pharmaceuticals (NASAQ:
DCPH). Following its Health Canada approval in June 2020, Deciphera entered into an exclusive
distribution agreement with Medison in November 2020 to commercialize the product in
Canada and Israel for the treatment of fourth-line
GIST.
Consult the complete QINLOCK Product Monograph for further
information on contraindications, warnings, precautions, adverse
reactions, and dosage and administration. The Product Monograph can
be found by visiting https://pdf.hres.ca/dpd_pm/00065750.PDF or by
calling 1-800-696-1341.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering,
developing, and commercializing important new medicines to improve
the lives of people with cancer. Deciphera is leveraging its
proprietary switch-control kinase inhibitor platform and deep
expertise in kinase biology to develop a broad portfolio of
innovative medicines. In addition to advancing multiple product
candidates from our platform in clinical studies, QINLOCK® is
Deciphera's switch-control inhibitor for the treatment of
fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New
Zealand, Singapore,
Switzerland, Taiwan, the United
Kingdom, and the United
States. For more information, visit www.deciphera.com.
About Medison Pharma
Medison is a global pharma company focused on providing access
to highly innovative therapies to patients in international
markets. Medison is the first to create an international
commercialization platform for highly innovative therapies, helping
to save and improve lives by making the best available novel
treatments accessible to patients in international markets. Medison
has a track record of multi-territorial partnerships with leading
pharmaceutical and biotech companies seeking to expand their global
reach. Medison is also an active investor in disruptive healthcare
technologies and provides its partners with exposure to innovation
in biotech and digital health. To learn more
visit www.medisonpharma.com
For additional information, please contact:
Medison Pharma
Inbal Chen, Corporate
Communications
M: +972 54 440 0784
E: inbalc@medisonpharma.com
Canadian media inquiries:
Dara Willis, Gage Communications
M: 416-836-9272
E: dwillis@gagecommunications.ca
[i] GIST Sarcoma Life Raft Group Canada (LRG
Canada). https://liferaftgroup.ca/about-gist/. Accessed
September 27, 2023.
[ii] QINLOCK Product Monograph.
https://pdf.hres.ca/dpd_pm/00065750.PDF
View original
content:https://www.prnewswire.co.uk/news-releases/medison-pharma-announces-public-formulary-listing-of-qinlock-ripretinib-in-canadian-provinces-ontario-and-quebec-for-advanced-gastrointestinal-stromal-tumor-gist-treatment-301942843.html